Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Kyle Rotherham

Physician Assistant, Surgical Omaha, NE Physician Assistant

NPI 1780397018 CMS profile 11512358

8005 Farnam Dr Ste 305, Omaha, NE 68114

Open in the dashboard

General payments

$2,369

26 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kyle Rotherham of Omaha, NE is reported in the CMS Open Payments database as having received $2,369 across 26 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17 1
2024 General $1,177 10
2023 General $1,174 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kyle Rotherham
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Kyle Rotherham were reported at $17. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Kyle Rotherham Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $111 $36–$285 $132
2022 $0 $126 $44–$350 $149
2023 $1,174 $137 $47–$355 $160
2024 $1,177 $146 $49–$384 $164
2025 $17 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Zimmer Biomet Holdings, Inc. $1,161 14 payments
  2. Conetic Solutions, Inc. $704 4 payments
  3. Arthrex, Inc. $490 7 payments
  4. Merck Sharp & Dohme Corporation $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Travel and Lodging $1,685 11 payments
  2. Food and Beverage $684 15 payments
Products named General payments · program years 2023–2025
  1. Comprehensive Shoulder System $901 9 payments
  2. ROSA $158 2 payments
  3. Juggerknotless Soft Anchor $102 3 payments
  4. DIFICID $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

614

Median for Physician Assistant: 241

Drug cost

$4,398

Median for Physician Assistant: $4,110

Branded share of claims

23.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 101 $1,039
Dexamethasone Generic 33 $457
Celecoxib Generic 15 $426
Cyclobenzaprine Hcl Generic 83 $420
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 41 $393
Tramadol Hcl Generic 115 $385
Diclofenac Sodium Generic 43 $365
Gabapentin Generic 18 $300
Ondansetron Hcl Generic 54 $187
Oxycodone Hcl Generic 12 $170

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$33,859

Of which drugs: $1,998

Medicare patients

300

Average age 76

Services billed

1,307

170 women, 130 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 30%
Chronic kidney disease 28%
Ischemic heart disease 27%
Atrial fibrillation 24%
Depression 22%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 62 604 $396
Injection, ketorolac tromethamine, per 15 mg J1885 Office 34 86 $39

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

26 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record